Nanjing Vazyme Biotech Co Ltd (688105) - Total Assets
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) holds total assets worth CN¥5.10 Billion CNY (≈ $746.43 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Nanjing Vazyme Biotech Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Nanjing Vazyme Biotech Co Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Nanjing Vazyme Biotech Co Ltd for net asset value and shareholders' equity analysis.
Nanjing Vazyme Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanjing Vazyme Biotech Co Ltd's total assets of CN¥5.10 Billion consist of 73.7% current assets and 26.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.0% |
| Accounts Receivable | CN¥444.01 Million | 8.8% |
| Inventory | CN¥343.67 Million | 6.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥86.63 Million | 1.7% |
| Goodwill | CN¥130.49 Million | 2.6% |
Asset Composition Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Nanjing Vazyme Biotech Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanjing Vazyme Biotech Co Ltd's current assets represent 73.7% of total assets in 2025, a decrease from 76.6% in 2017.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2025, down from 47.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 8.8% of total assets.
Nanjing Vazyme Biotech Co Ltd Competitors by Total Assets
Key competitors of Nanjing Vazyme Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Nanjing Vazyme Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.39 | 3.33 | 5.59 |
| Quick Ratio | 3.08 | 3.01 | 4.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.69 Billion | CN¥2.70 Billion | CN¥1.37 Billion |
Nanjing Vazyme Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nanjing Vazyme Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | CN¥5.03 Billion |
| Market Capitalization | $1.48 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Nanjing Vazyme Biotech Co Ltd's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Nanjing Vazyme Biotech Co Ltd's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual total assets of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.03 Billion ≈ $735.75 Million |
-0.41% |
| 2024-12-31 | CN¥5.05 Billion ≈ $738.78 Million |
-12.14% |
| 2023-12-31 | CN¥5.75 Billion ≈ $840.85 Million |
-4.31% |
| 2022-12-31 | CN¥6.01 Billion ≈ $878.75 Million |
+30.35% |
| 2021-12-31 | CN¥4.61 Billion ≈ $674.17 Million |
+185.87% |
| 2020-12-31 | CN¥1.61 Billion ≈ $235.83 Million |
+396.91% |
| 2019-12-31 | CN¥324.33 Million ≈ $47.46 Million |
+29.35% |
| 2018-12-31 | CN¥250.75 Million ≈ $36.69 Million |
+33.10% |
| 2017-12-31 | CN¥188.40 Million ≈ $27.57 Million |
-- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more